The prevention of colitis-related cancer by 5-aminosalicylates: An appealing hypothesis that remains unproven

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 737-740

  Terdiman, Jonathan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; MESALAZINE; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RISK; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMOPROPHYLAXIS; COLON BIOPSY; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE DURATION; DNA DAMAGE; DOSE RESPONSE; HUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLORECTAL NEOPLASMS; HUMANS; MESALAMINE; MODELS, THEORETICAL;

EID: 79953805347     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.56     Document Type: Review

References (21)

1. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-20. (Pubitemid 24195353)
2. Bernstein CN, Nugent Z, Blanchard JF. A population-based study of 5-aminosalicylate use and colorectal cancer in IBD. Am J Gastroenterol 2011;106:731-6(thisissue).
3. Bergeron V, Vienne A, SokolH et al Risk factors for neoplasia in Infammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010;105:2405-11.
4. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenha-gen County. Clin Gastroenterol Hepatol 2004;2:1088-95. (Pubitemid 40037640)
5. Rutter M, Saunders B, Wilkinson K et al. Severity of Infammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
6. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with Infammatory bowel disease. Cochrane Database Syst Rev 2006; 19: CD000279.
7. Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ter 2010;31:202-9.
8. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C 5-ASA af ects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007;132:221-35. (Pubitemid 46108738)
9. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replica-tion f delity in cultured colorectal cells. Cancer Res 2005; 65: 3993-7. (Pubitemid 40775634)
10. Campregher C, Honeder C, Chung H, Carethers JM, Gasche C Mesalazine reduces mutation in transforming growth factor beta rector II and activin type II receptor by improvement of replication f delity in mononucleotide repeats. Clin Cancer Res 2010; 16: 1950-6.
11. Brown JB, Lee G, Managlia E et al Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 2010;138:595-605.
12. Deeks JJ, Dinnes J, D ' Amico R et al. Evaluating non-randomized intervention studies. Health Technol Assess 2003;7:1-173.
13. Vandenbroucke JP, von Elm E, Altman DG et al STROBE Initiative. Strengthening the reporting of observational studies in epidemiology: explanation and elaboration. Ann Intern med 2007;147:W163-94. (Pubitemid 351664503)
14. Teaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis. Aliment Pharmacol Ter 2000;14:145-53. (Pubitemid 30088290)
15. van Staa TP, Card T, Logan RF, Leufens HGM. 5-aminosalicylate use and colorectal cancer risk in Infammatory bowel disease: a large epidemiologi-cal study. Gut 2005;54:1573-8. (Pubitemid 41531774)
16. Velayos FS, Lofus EV, Jess Tet al Predictive and protective factors as-sociated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130:1941-9. (Pubitemid 43816957)
17. Jess T, Lofus EV, Velayos FS et al. Risk factors for colorectal neoplasia in inf am-matory bowel disease: a nested case-control study from Copenhagen county Denmark and Olmsted county Minnesota. Am J Gastroenterol 2007; 102: 829-36. (Pubitemid 46496613)
18. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT 5-Ami-nosalicylic acid therapy and the risk of colorectal cancer among patients with infammatorybowel disease. Infamm Bowel Dis 2007;13:367-71. (Pubitemid 46668239)
19. Bernstein CN, Metge C, Blanchard JF, Yogendran M. Does the use of 5-aminosalicylates in Infammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8. (Pubitemid 38020124)
20. Velayos FS, Terdiman JP Walsh JM. effect of 5-aminosalicylate on color-ectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 1995; 100: 1345-53.
21. Carrat F, Seksik P, Bouvier AM et al Aminosalicylates, thiopurines and the risk of colorectal cancer in Infammatory bowel disease: a case-control study nested in the CESAME cohort. Gastroenterology 2010; 138: S-47 (A 255).